Chitosan nanoparticles as a new delivery system for the chemotherapy agent tegafur

Drug Development and Industrial Pharmacy

Volumn 36, Issue 6, 2010, Pages 744-750

  Arias, José L ^a   López Viota, Margarita ^a   Gallardo, Visitación ^a   Adolfina Ruiz, María ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Antitumor drug; Cancer targeting; Controlled release; Drug carriers; Polymeric colloids

Indexed keywords

CHITOSAN; NANOPARTICLE; NANOSPHERE; PERMANGANATE POTASSIUM; POLOXAMER; TEGAFUR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; ELECTROPHORETIC MOBILITY; LIGHT SCATTERING; LIPOPHILICITY; PARTICLE SIZE; QUANTITATIVE ANALYSIS; THERMODYNAMICS;

ANTIMETABOLITES, ANTINEOPLASTIC; CHITOSAN; DRUG DELIVERY SYSTEMS; NANOPARTICLES; TEGAFUR;

EID: 77952524536     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903517914     Document Type: Article

References (25)

1. Cooke JWB, Bright R, Coleman MJ, Jenkins KP. (2001). Process research and development of a dihydropyrimidine dehydrogenase inactivator: Large-scale preparation of enuracil using a sonogashira coupling. Org Process Res Dev, 5:383-6.
2. Zhang N, Yin Y, Xu SJ, Chen WS. (2008). 5-fluorouracil: Mechanisms of resistance and reversal strategies. Molecules, 13:1551-69.
3. Arias JL. (2008). Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules, 13:2340-69.
4. Couvreur P, Vauthier C. (2006). Nanotechnology: Intelligent design to treat complex disease. Pharm Res, 23:1417-50.
5. Illum L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharm Res, 15:1326-31.
6. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et al. (2004). Chitosan microspheres as a potential carrier for drugs. Int J Pharm, 274:1-33.
7. Nordtveit RJ, Vårum KM, Smidsrød O. (1994). Degradation of fully water-soluble, partially N-acetylated chitosans with lysozyme. Carbohydr Polym, 23:253-60.
8. Pitt CG. (1990). The controlled parenteral delivery of polypeptides and proteins. Int j Pharm, 59:173-96.
9. Thanoo BC, Sunny MC, Jayakrishnan A. (1992). Cross-linked chitosan microspheres: Preparation and evaluation as a matrix for the controlled release of pharmaceuticals. J Pharm Pharmacol, 44:283-6.
10. Berthold A, Cremer K, Kreuter J. (1996). Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. J Control Release, 39:17-25.
11. Fawaz F, Guyot M, Lagueny AM, Devissaguet JPh. (1997). Ciprofloxacin loaded polyisobutylcyanoacrylate nanoparticles: Preparation and characterization. Int J Pharm, 154:191-203.
12. Sullivan CO, Birkinshaw C. (2004). In vitro degradation of insulin-loaded poly (n-butylcyanoacrylate) nanoparticles. Biomaterials, 25:4375-82.
13. Arias JL, Ruiz MA, Gallardo V, Delgado AV. (2008). Tegafur loading and release properties of magnetite/poly (alkylcyanoacrylate) (core/shell) nanoparticles. J Control Release, 125:50-8.
14. Arias JL, Reddy LH, Couvreur P. (2009). Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target, 17:586-98.
15. Arias JL, Gallardo V, Ruiz MA, Delgado AV. (2007). Ftorafur loading and controlled release from poly (ethyl-2-cyanoacrylate) and poly (butylcyanoacrylate) nanospheres. Int J Pharm, 337:282-90.
16. Elsabee MZ, Morsi RE, Al-Sabagh AM. (2009). Surface active properties of chitosan and its derivatives. Colloids Surf B Biointerfaces, 74:1-16.
17. Leodinov NB. (2003). Crystalline modification of 5-fluoro-1- (tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect. US patent no. 6538001.
18. Llovet MI, Egea MA, Valero J, Alsina MA, García ML, Chauvet A. (1995). Methotrexate-loaded nanoparticles: Analysis of drug content and study of the matrix structure. Drug Dev Ind Pharm, 21:1761-71.
19. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 70:1-20.
20. Stolnik S, Illum L, Davis SS. (1995). Long circulating microparticulate drug carriers. Adv Drug Deliv Rev, 16:195-214.
21. McCarron PA, Woolfson AD, Keating SM. (2000). Sustained release of 5-fluorouracil from polymeric nanoparticles. J Pharm Pharmacol, 52:1451-9.
22. Ko JA, Park HJ, Hwang SJ, Park JB, Lee JS. (2002). Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int J Pharm, 249:165-74.
23. Manca ML, Loy G, Zaru M, Fadda AM, Antimisiaris SG. (2008). Release of rifampicin from chitosan, PLGA and chitosancoated PLGA microparticles. Colloids Surf B Biointerfaces, 67:166-70.
24. Papadimitriou S, Bikiaris D, Avgoustakis K, Karavas E, Georgarakis M. (2008). Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym, 73:44-54.
25. Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B. (2009). Chitosan nanoparticles as a new delivery system for the anti-Alzheimer's drug tacrine. Nanomedicine: NBM. doi:10.1016/j.nano. 2009.04.001.